Comparative Pharmacology
Head-to-head clinical analysis: BETAMETHASONE versus BREO ELLIPTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAMETHASONE versus BREO ELLIPTA.
Betamethasone vs BREO ELLIPTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betamethasone is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to modulation of gene expression, resulting in anti-inflammatory and immunosuppressive effects. It also suppresses the hypothalamic-pituitary-adrenal axis.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
0.6 to 9 mg/day orally in divided doses; intramuscularly, 0.5 to 9 mg/day; intravenously, up to 12 mg/day; topical (as valerate or dipropionate) applied thinly to affected area once to twice daily.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
None Documented
None Documented
Clinical Note
moderateBetamethasone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Gatifloxacin."
Clinical Note
moderateBetamethasone + Rosoxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Rosoxacin."
Clinical Note
moderateBetamethasone + Levofloxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Levofloxacin."
Clinical Note
moderateTerminal half-life: 6.4 hours (range 4.3-9.4 hours). Clinically, adrenal suppression lasts 2.7-3.5 days after single dose.
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Primarily renal: ~60% as metabolites, <5% unchanged. Biliary/fecal: ~15-20%.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Category A/B
Category C
Corticosteroid
Corticosteroid/Beta-2 Agonist Combination
Betamethasone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Trovafloxacin."